The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer

Ash, D.; Al-Qaisieh, B.; Bottomley, David; Carey, B.; Joseph, Joji

doi:10.1016/j.radonc.2005.03.015

Cited by 44 publications

(33 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that short-term hormone therapy was the most important prognostic factor in univariate and multivariate analyses. On the other hand, Potters et al [17] and Ash et al [18] reported that neoadjuvant short-term ADT for a mean of 3-4 months had no clinical benefit in patients with localized prostate cancer. In those previous reports, the patients received NHT for only about 3-4 months, which may not have been long enough to achieve significant benefit.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

Senzaki¹,

Fukumori²,

Mori³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Introduction: The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥6 months in patients with localized prostate cancer. Patients and Methods: A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. Results: BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) <180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Conclusions: Neoadjuvant CAB for ≥6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

Senzaki¹,

Fukumori²,

Mori³

et al. 2015

Urol Int

View full text Add to dashboard Cite

show abstract

“…These results are in agreement with a previous report. 19 Ash and coworkers reported that postimplant prostate D90 was significantly different between patients who had and had not undergone NHT (130.8 vs. 145.1 Gy, P ≤ 0.001). 19 A possible explanation for the negative effect of NHT on postimplant prostate D90 is that NHT is associated with an increase in prostate volume after implantation, which results in a lower D90.…”

Section: Discussionmentioning

confidence: 99%

“…19 Ash and coworkers reported that postimplant prostate D90 was significantly different between patients who had and had not undergone NHT (130.8 vs. 145.1 Gy, P ≤ 0.001). 19 A possible explanation for the negative effect of NHT on postimplant prostate D90 is that NHT is associated with an increase in prostate volume after implantation, which results in a lower D90. 19 Ash and coworkers reported that the ratio of the postimplant CT scan volume to the preimplant TRUS volume of the prostate (CT/TRUS volume ratio), which indicates the volume change of the prostate from before to after implantation, was significantly different between patients who had and had not undergone NHT (1.17 vs. 0.98, P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

“…19 A possible explanation for the negative effect of NHT on postimplant prostate D90 is that NHT is associated with an increase in prostate volume after implantation, which results in a lower D90. 19 Ash and coworkers reported that the ratio of the postimplant CT scan volume to the preimplant TRUS volume of the prostate (CT/TRUS volume ratio), which indicates the volume change of the prostate from before to after implantation, was significantly different between patients who had and had not undergone NHT (1.17 vs. 0.98, P < 0.001). 19 Our previous study also showed that the CT/TRUS volume ratio was significantly different between patients who had and had not undergone NHT (1.30 vs. 1.05, P < 0.001), meaning that patients who had undergone NHT had a greater increase in prostate volume after implantation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Preimplant Factors Affecting Prostate D90 after Transperineal Interstitial Prostate Brachytherapy with Loose 125I Seeds

et al. 2012

View full text Add to dashboard Cite

“…Brachytherapy is commonly used for effective treatment of cervical, prostate, breast and skin cancers and can also be used to treat tumours in many other body sites. [1][2][3][4][5] Brachytherapy can be used alone or in combination with other modalities such as surgery, chemotherapy and external beam radiotherapy (EBRT). Initially treatments were given based on individual experiences and clinical judgment ability.…”

Section: Introductionmentioning

confidence: 99%

Impact of discrete source step size on the 3D dosimetry of interstitial implants with high dose rate brachytherapy

Maurya

et al. 2018

Int J Res Med Sci

View full text Add to dashboard Cite

Background: High dose rate remote after loading brachytherapy machines have seen tremendous advancement both technologically and their clinical applications during the last 25 years. With the introduction of computerized remote after loading machines and computerized planning system, stepping source dosimetry system (SSDS) has become the system of choice making almost all traditional dosimetry systems obsolete. In this study we evaluated the impact of source step size on dosimetry of interstitial implant using parameters of ICRU-58 and various quality indices (QI).Material & Methods: For this study, 10 implant cases which have 3-D CT image based planning were selected. Contouring of clinical target volume and various organs were done following standard guidelines for the same. Plans were optimized to achieve the desired clinical outcome using different source step sizes of 2.5, 5 and 10 mm respectively. Cumulative DVH’s were calculated for the estimation of various ICRU-58 parameters and quality indices.Results and Conclusion: The mean values of the target volumes, minimum target doses, treated volumes, low dose volumes; high dose volumes, overdose volumes, reference volumes, coverage, external volume, relative dose homogeneity, overdose volume and COIN indices have been presented for the source step sizes of 2.5 mm, 5 mm and 10 mm respectively. Among source step sizes used in this study, most favorable clinically acceptable dose distributions & dose homogeneity occurs around step size of 5 mm as predicted by the various parameters of ICRU-58 and dose quality indices. Keywords: Brachytherapy, interstitial implant, source step-size, remote after loading, optimization, quality indices.

show abstract

The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer

Cited by 44 publications

References 6 publications

Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy

Preimplant Factors Affecting Prostate D90 after Transperineal Interstitial Prostate Brachytherapy with Loose 125I Seeds

Impact of discrete source step size on the 3D dosimetry of interstitial implants with high dose rate brachytherapy

Contact Info

Product

Resources

About